Oral Mucositis Market expected to rise | Companies – Galera Therapeutics, Soligenix, Izun Pharma, MitoImmune Therapeutics, Tosk, Cellix Bio, Monopar Therapeutics, expected to drive market

Oral Mucositis Market expected to rise | Companies – Galera Therapeutics, Soligenix, Izun Pharma, MitoImmune Therapeutics, Tosk, Cellix Bio, Monopar Therapeutics, expected to drive market

June 09
12:04 2023
Oral Mucositis Market expected to rise | Companies - Galera Therapeutics, Soligenix, Izun Pharma, MitoImmune Therapeutics, Tosk, Cellix Bio, Monopar Therapeutics, expected to drive market
Oral Mucositis Market
DelveInsight’s “Oral Mucositis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Oral Mucositis, historical and forecasted epidemiology as well as the Oral Mucositis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Oral Mucositis market growth is driven by factors like increase in the prevalence of Oral Mucositis, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Oral Mucositis market report also offers comprehensive insights into the Oral Mucositis market size, share, Oral Mucositis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Oral Mucositis market size growth forward. 

Some of the key highlights from the Oral Mucositis Market Insights Report:

  • Several key pharmaceutical companies, including Galera Therapeutics, Soligenix, Izun Pharma, MitoImmune Therapeutics, Tosk, Cellix Bio, Enzychem Lifesciences, Monopar Therapeutics, and others, are developing novel products to improve the Oral Mucositis treatment outlook. 
  • The total Oral Mucositis market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
  • As per DelveInsight analysis, the Oral Mucositis market is anticipated to witness growth at a considerable CAGR
  • The total Oral Mucositis incident cases in 7MM in 2017 were 1,418,879.

Strategise your business goals by understanding market dynamics @ Oral Mucositis Market Landscape

Oral Mucositis Overview 

Mucositis occurs when cancer treatments break down the rapidly divided epithelial cells lining the gastro-intestinal tract (which goes from the mouth to the anus), leaving the mucosal tissue open to ulceration and infection. Mucosal tissue, also known as mucosa or the mucous membrane, lines all body passages that communicate with the air, such as the respiratory and alimentary tracts, and have cells and associated glands that secrete mucus. The part of this lining that covers the mouth, called the oral mucosa, is one of the most sensitive parts of the body and is particularly vulnerable to chemotherapy and radiation. The oral cavity is the most common location for mucositis. Oral mucositis is probably the most common, debilitating complication of cancer treatments, particularly chemotherapy and radiation. It can lead to several problems, including pain, nutritional problems as a result of inability to eat, and increased risk of infection due to open sores in the mucosa. It has a significant effect on the patient’s quality of life and can be dose-limiting (i.e., requiring a reduction in subsequent chemotherapy doses).

Do you know the treatment paradigms for different countries? Download our Oral Mucositis Market Sample Report

Oral Mucositis Epidemiology Segmentation 

DelveInsight’s Oral Mucositis market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Oral Mucositis historical patient pools and forecasted Oral Mucositis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Oral Mucositis Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

  • Oral Mucositis Prevalence 
  • Age-Specific Oral Mucositis Prevalence 
  • Gender-Specific Oral Mucositis Prevalence 
  • Diagnosed and Treatable Cases of Oral Mucositis

Visit for more @ Oral Mucositis Epidemiological Insights

Oral Mucositis Treatment Market 

The Oral Mucositis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Oral Mucositis market trends by analyzing the impact of current Oral Mucositis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Oral Mucositis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Oral Mucositis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Oral Mucositis market in 7MM is expected to witness a major change in the study period 2019-2032.

Oral Mucositis Therapy Assessment

GC4419: Galera Therapeutics

GC4419, also known as avasopasem manganese, has successfully completed two clinical trials in which it was evaluated for reduction of severe oral mucositis in patients with head and neck cancer undergoing radiation therapy and also receiving cisplatin, a chemotherapy drug. The drug is currently in phase III stage of clinical trial evaluation to treat Oral Mucositis.

SGX942: Soligenix

SGX942 is unique in its mechanism addressing the underlying innate immune dysfunction that contributes to the severity and duration of mucositis. Administered twice weekly by a brief 4-minute IV infusion during chemoradiation treatment while patients are otherwise present at their clinician’s office or hospital, SGX942 may be a clinically convenient and safe approach to mitigating oral mucositis. Company’s pivotal Phase 3 clinical study (“DOM-INNATE”) for oral mucositis in head and neck cancer patients has completed enrollment.

Oral Mucositis Key Companies

  • Galera Therapeutics
  • Soligenix
  • Izun Pharma
  • MitoImmune Therapeutics
  • Tosk
  • Cellix Bio
  • Enzychem Lifesciences
  • Monopar Therapeutics

Oral Mucositis Pipeline Drugs

  • Brilacidin
  • EC-18
  • Corral System
  • CareMin650
  • Validive (Clonidine Lauriad)
  • MuReva Phototherapy System
  • RRx-001
  • SGX942
  • Vasospasm (GC4419)
  • And many others.

For more information, visit Oral Mucositis Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Oral Mucositis Market Report:

  • 11 Years Forecast
  • 7MM Coverage 
  • Descriptive overview of Oral Mucositis, causes, signs and symptoms, diagnosis, treatment
  • Comprehensive insight into Oral Mucositis epidemiology in the 7MM
  • Oral Mucositis marketed and emerging therapies 
  • Oral Mucositis companies
  • Oral Mucositis market drivers and barriers 

Key Questions Answered in the Oral Mucositis Market Report 2032:

  • What was the Oral Mucositis market share distribution in 2019, and how would it appear in 2032?
  • What is the total Oral Mucositis market size and the market size by therapy across the 7MM for the study period (2019-32)?
  • What are the important findings from 7MM, and which country will have the greatest Oral Mucositis market size from 2019-32?
  • During the study period (2019-2032), at what CAGR is the Oral Mucositis market projected to expand at 7MM?

Table of Contents:

1 Oral Mucositis Market Key Comprehensive Insights 

2 Oral Mucositis Market Report Introduction

3 Competitive Intelligence Analysis for Oral Mucositis

4 Oral Mucositis Market Analysis Overview at a Glance

5 Executive Summary of Oral Mucositis

6 Oral Mucositis Epidemiology and Market Methodology

7 Oral Mucositis Epidemiology and Patient Population

8 Oral Mucositis Patient Journey

9 Oral Mucositis Treatment Algorithm, Oral Mucositis Current Treatment, and Medical Practices

10 Key Endpoints in Oral Mucositis Clinical Trials

11 Oral Mucositis Marketed Therapies 

12 Oral Mucositis Emerging Therapies

13 Oral Mucositis: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Oral Mucositis

16 Oral Mucositis Market Key Opinion Leaders Reviews

18 Oral Mucositis Market Drivers

19 Oral Mucositis Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Oral Mucositis Epidemiology 2032

DelveInsight’s “Oral Mucositis – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Oral Mucositis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Oral Mucositis Pipeline 2023

“Oral Mucositis Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Oral Mucositis market. A detailed picture of the Oral Mucositis pipeline landscape is provided, which includes the disease overview and Oral Mucositis treatment guidelines. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/